Skip to main content
ODTX logo

Odyssey Therapeutics, Inc.

ODTXNASDAQHealthcareBiotechnology

$17.17Today:- (-)

As of Oct 16, 2026 close

Market cap
$531.97M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$15.10$29.05
Volume (live)
-
Avg. volume (3M)
363.00K

Odyssey Therapeutics (ODTX) Key Statistics & Financial Metrics

Complete stock analysis with 60+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Stock Price

Current price, 52-week range, and moving averages

Current Price$17.17
1-Day Change+5.84%
52-Week High$29.05
52-Week Low$15.10
YTD Change+7.00%
50-Day MA$22.47
Avg Volume (30 day)363.00K

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Price Target$34.33
Target Upside/Downside+99.94%
Analyst ConsensusBuy
Analyst Count4

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth−33.45%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Source: Market prices and company fundamentals from financial filings. Data as of Oct 16, 2026. Data sources and methodology

Frequently Asked Questions About Odyssey Therapeutics Statistics

What are the key financial metrics for ODTX?

Odyssey Therapeutics, Inc. (ODTX) statistics include 60+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is ODTX's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Odyssey Therapeutics is overvalued or undervalued.

How do I read ODTX's profitability ratios?

Odyssey Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do ODTX's debt ratios indicate?

The financial health section shows Odyssey Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is ODTX's dividend analysis?

The dividend section covers Odyssey Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.